SCHEMBL6474047

SCHEMBL6474047

CCCS(=O)(=O)NCC(C)Oc1ccc(-c2cccc(C)c2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 1/20 0.44
PPARA Q07869 1/20 0.44
GRIA4 P48058 1/20 0.41
MMP1 P03956 1/20 0.38
MMP2 P08253 1/20 0.38
MMP3 P08254 1/20 0.38
MMP7 P09237 1/20 0.38
MMP9 P14780 1/20 0.38
MMP8 P22894 1/20 0.38
MMP13 P45452 1/20 0.38
MMP14 P50281 1/20 0.38
MTNR1A P48039 3/20 0.38
MTNR1B P49286 3/20 0.38
FNTA P49354 1/20 0.37
FNTB P49356 1/20 0.37
ALDH1A1 P00352 1/20 0.36
KMT2A Q03164 1/20 0.36
ADRB2 P07550 1/20 0.35
ADRB1 P08588 1/20 0.35
MAPT P10636 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6474393 0.88 GRIA4 (0.43) PPARGPPARAGRIA4MMP2MMP9
SCHEMBL6475297 0.88 GRIA4 (0.48) PPARGPPARAGRIA4MMP8MMP13
SCHEMBL6482324 0.88 GRIA4 (0.46) GRIA4MMP1MMP2MMP3MMP7
SCHEMBL6479543 0.87 GRIA4 (0.45) GRIA4MMP1MMP2MMP3MMP7
SCHEMBL6474219 0.87 MTNR1A (0.50) GRIA4MTNR1AMTNR1B
SCHEMBL6474430 0.87 PLAU (0.40) GRIA4MTNR1AMTNR1BMAPTCA12
SCHEMBL6474263 0.87 GRIA4 (0.40) GRIA4MMP1MMP2MMP3MMP7
SCHEMBL6481819 0.86 SMN1; SMN2 (0.44) GRIA4KMT2ATP53SMN1; SMN2
SCHEMBL6481274 0.85 CA12 (0.41) GRIA4MTNR1AMTNR1BMAPTCA12
SCHEMBL6474298 0.84 KIF11 (0.46) GRIA4KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030225266-A1 Sulfonamide derivatives ELI LILLY AND COMPANY 2003-12-04 US claimed
EP-1265857-A1 SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2002-12-18 EP claimed
WO-2001068592-A1 SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2001-09-20 WO claimed
US-6911476-B2 Sulfonamide derivatives ELI LILLY AND COMPANY (US) 2005-06-28 US disclosed
US-20030225266-A1 Sulfonamide derivatives ELI LILLY AND COMPANY 2003-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225266-A1 Sulfonamide derivatives GRIN2A, GRM2, GRIA2 PPARG 828/4885PPARA 1066/4885GRIA4 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.